Vera Hirsh

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications
    Vera Hirsh
    McGill University, Montreal, Quebec, Canada
    Clin Lung Cancer 6:170-4. 2004
  2. ncbi Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Vera Hirsh
    Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, Room A2 04, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Anticancer Agents Med Chem 12:137-43. 2012
  3. ncbi Emerging safety data for bevacizumab in advanced non-small-cell lung cancer
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    Clin Lung Cancer 9:S62-70. 2008
  4. ncbi Afatinib (BIBW 2992) development in non-small-cell lung cancer
    Vera Hirsh
    McGill University, Department of Medicine and Oncology, Royal Victoria Hospital, Montreal, Quebec, Canada
    Future Oncol 7:817-25. 2011
  5. ncbi Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer
    Vera Hirsh
    McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
    J Clin Oncol 29:2667-74. 2011
  6. ncbi Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    Clin Lung Cancer 10:223-9. 2009
  7. ncbi Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    J Thorac Oncol 3:228-36. 2008
  8. ncbi Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer
    Vera Hirsh
    Division of Medical Oncology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada
    J Thorac Oncol 2:927-32. 2007
  9. ncbi Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial
    Vera Hirsh
    Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
    Am J Clin Oncol 30:245-51. 2007
  10. ncbi Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial
    Vera Hirsh
    Royal Victoria Hospital, McGill University, 687 Pine Avenue W, Montreal, Que, Canada H3A 1A1
    Lung Cancer 49:117-23. 2005

Detail Information

Publications18

  1. ncbi Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications
    Vera Hirsh
    McGill University, Montreal, Quebec, Canada
    Clin Lung Cancer 6:170-4. 2004
    ..5 months (P = 0.534). This exploratory analysis demonstrates that patients with a history of SREs are at high risk for subsequent SREs, but zoledronic acid reduces skeletal morbidity regardless of SRE history...
  2. ncbi Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Vera Hirsh
    Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, Room A2 04, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Anticancer Agents Med Chem 12:137-43. 2012
    ..This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies...
  3. ncbi Emerging safety data for bevacizumab in advanced non-small-cell lung cancer
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    Clin Lung Cancer 9:S62-70. 2008
    ..Recommendations for the monitoring and management of bevacizumab-associated adverse events are discussed...
  4. ncbi Afatinib (BIBW 2992) development in non-small-cell lung cancer
    Vera Hirsh
    McGill University, Department of Medicine and Oncology, Royal Victoria Hospital, Montreal, Quebec, Canada
    Future Oncol 7:817-25. 2011
    ..Further Phase III clinical trials are currently ongoing to assess afatinib in combination with paclitaxel (LUX-Lung 5), and compared with cisplatin/pemetrexed (LUX-Lung 3) or cisplatin/gemcitabine (LUX-Lung 6)...
  5. ncbi Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer
    Vera Hirsh
    McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
    J Clin Oncol 29:2667-74. 2011
    ....
  6. ncbi Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    Clin Lung Cancer 10:223-9. 2009
    ..Additional ongoing clinical trials are assessing further benefits and antitumor activity of zoledronic acid in the adjuvant setting in the prevention of bone metastases in patients with lung cancer...
  7. ncbi Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    J Thorac Oncol 3:228-36. 2008
    ..Zoledronic acid (ZOL) reduces SRE risk and NTX levels...
  8. ncbi Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer
    Vera Hirsh
    Division of Medical Oncology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada
    J Thorac Oncol 2:927-32. 2007
    ..The role of induction chemotherapy with carboplatin/gemcitabine regimen has not been established in stage III NSCLC...
  9. ncbi Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial
    Vera Hirsh
    Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
    Am J Clin Oncol 30:245-51. 2007
    ..Many patients with metastatic nonsmall cell lung carcinoma (NSCLC) cannot tolerate intravenous chemotherapy. Orally active agents would be more convenient and thus could improve their quality of life...
  10. ncbi Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial
    Vera Hirsh
    Royal Victoria Hospital, McGill University, 687 Pine Avenue W, Montreal, Que, Canada H3A 1A1
    Lung Cancer 49:117-23. 2005
    ..We evaluated a sequential treatment with Vinorelbine followed by Gemcitabine to determine its effect on survival and the toxicity in this patient population...
  11. ncbi Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial
    Vera Hirsh
    Division of Medical Oncology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
    Cancer 97:2242-7. 2003
    ....
  12. ncbi Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial
    Vera Hirsh
    Medical Oncology Division, Room A2 04, Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    Lung Cancer 46:113-8. 2004
    ..Hematologic toxicity was minimal, non-hematologic toxicity was easily treatable. Docetaxel, when given with Gemcitabine on days 1 and 8 every 3 weeks, is less myelotoxic, yet still an effective treatment for metastatic NSCLC...
  13. ncbi Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA
    Cancer 100:2613-21. 2004
    ..In the current study, they update these results and report the long-term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo-controlled trial...
  14. ncbi Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer
    Christian Manegold
    University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
    J Clin Oncol 26:3979-86. 2008
    ..This study assessed the efficacy of the combination of standard taxane plus platinum chemotherapy with the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in patients with non-small-cell lung cancer (NSCLC)...
  15. ncbi Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials
    Cesare Gridelli
    Clinical Trials Unit, National Cancer Institute, Via M Semmola, 80131 Naples, Italy
    J Clin Oncol 21:3025-34. 2003
    ..This trial aimed to assess whether a combination of gemcitabine and vinorelbine had benefits in terms of QoL, without influencing negatively on survival, compared with cisplatin-containing regimens...
  16. ncbi Erlotinib in previously treated non-small-cell lung cancer
    Frances A Shepherd
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada
    N Engl J Med 353:123-32. 2005
    ..CONCLUSIONS: Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy. Copyright 2005 Massachusetts Medical Society...
  17. ncbi Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
    Frances A Shepherd
    National Cancer Institute of Canada Clinical Trials Group
    J Clin Oncol 20:4434-9. 2002
    ..This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy...
  18. ncbi Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    Lee S Rosen
    Cancer Institute Medical Group, 11818 Wilshire Blvd, Suite 200, Los Angeles, CA 90025, USA
    J Clin Oncol 21:3150-7. 2003
    ..To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer...